Your search
Results 7 resources
-
Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ transplantation. This high burden of disease, which incurs sizeable morbidity, may be worsening with the proportion of high-risk D+/R− solid organ transplantation recipients increasing in some regions globally. Cohort studies continue to support either universal prophylaxis or preemptive therapy as effective prevention strategies. Letermovir prophylaxis was noninferior to valganciclovir in adult high-risk...
-
What is already known about this topic? Immunocompromised persons experience a higher incidence of herpes zoster and related complications. On July 23, 2021, the Food and Drug Administration expanded the indication for use of recombinant zoster vaccine (RZV) to include immunodeficient or immunosuppressed adults. What is added by this report? On October 20, 2021, the Advisory Committee on Immunization Practices recommended 2 RZV doses for prevention of herpes zoster and related complications...
-
Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and...
-
BACKGROUND: This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24% respectively cleared cytomegalovirus DNA at week 8 (treatment responders). METHODS: Baseline and post-treatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54 and UL27. RESULTS: At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet or...
-
Export
-
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians,...
Filter by our tag
GUIDELINES
- AST Guidelines 2019 (1)
- TTS Guidelines (1)
ORGANISMS
-
VIRUSES
-
CMV
(5)
- Cell-Mediated Immunity Assays (1)
- Clinical (3)
- Letermovir (2)
- Maribavir (3)
- Preemptive Therapy (1)
- Measles (1)
- VZV (1)
-
CMV
(5)
PREVENTION
- Vaccination (1)
ARTICLE OF THE MONTH
- 2023 (1)
ATC 2024 Top Papers in TID
- VIRUSES (1)